Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 34Lung Neoplasms 9Small Cell Lung Carcinoma 8Pancreatic Neoplasms 7Prostatic Neoplasms 5Ovarian Neoplasms 4Head and Neck Neoplasms 4Colorectal Neoplasms 4Breast Neoplasms 4Sarcoma 3Melanoma 3Carcinoma, Renal Cell 3Carcinoma 3Thyroid Neoplasms 2Neoplasms 2Chondrosarcoma 2Cholangiocarcinoma 2Carcinoma, Medullary 2Carcinoma, Hepatocellular 2Adenocarcinoma of Lung 2Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Thoracic Neoplasms 1Stomach Neoplasms 1Squamous Non-Small Cell Lung Cancer 1Sarcoma, Synovial 1Rhabdoid Tumor 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Recurrence 1

Interventions

AMG 757 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Bites and Stings × Thoracic × Clear all
NCT06064500 2025-03-10

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

Amgen

Approved for marketing
Thoracic

Bites and Stings, Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡